Myeloproliferative Neoplasms

MPN-Directed Therapy Does Not Alter Timing of Clinical Manifestations of Splanchnic Vein Thrombosis

By

Susan Moench, PhD, PA-C

Publish Date December 2, 2019

A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.

RBC Count, Erythrocyte Sedimentation Rate May Be Useful Biomarkers of Polycythemia Vera

By

Susan Moench, PhD, PA-C

Publish Date November 11, 2019

Although some red blood cell-related parameters used in the diagnosis of PV may be misleading in the setting of iron-deficiency, RBC count may be an effective biomarker for PV when combined with ESR.

Salvage Therapy With Pegylated Interferon Alfa-2a Benefits High-Risk Myeloproliferative Neoplasms Previously Treated With Hydroxyurea

By

Susan Moench, PhD, PA-C

Publish Date November 4, 2019

This nonrandomized study enrolled more than 100 patients with essential thrombocythemia or polycythemia vera resistant to or intolerant of hydroxyurea to determine if interferon alfa-2a is effective in these patients.

Evaluating Approaches for Improving Pregnancy Outcomes for Women With Myeloproliferative Neoplasms

By

Susan Moench, PhD, PA-C

Publish Date October 23, 2019

This meta-analysis evaluated the effects of different therapeutic approaches on the live birth rate and maternal outcomes of pregnant women with MPNs.

Blood Cell Count Monitoring May Predict Progression of ET, PV to Secondary Myelofibrosis

By

Susan Moench, PhD, PA-C

Publish Date October 21, 2019

Identifying progressive anemia and thrombocytopenia in patients with PV or ET may be predictive of MPN progression to secondary myelofibrosis.